n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Cardiac Hypertrophy in 3 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A rat aortic banding model of cardiac hypertrophy was used to test the hypothesis that reversible inhibition of mitochondrial respiration by nitric oxide (NO*) elicits a bioenergetic defect in the hypertrophied heart." | 1.31 | Bioenergetics in cardiac hypertrophy: mitochondrial respiration as a pathological target of NO*. ( Anderson, PG; Brookes, PS; Dai, L; Darley-Usmar, VM, 2001) |
| "ACF induced cardiac hypertrophy in rats with compensated (36%) and decompensated (76%) HF." | 1.31 | Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. ( Abassi, Z; Binah, O; Gealekman, O; Rubinstein, I; Winaver, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, P | 1 |
| Xu, X | 1 |
| Hu, X | 1 |
| van Deel, ED | 1 |
| Zhu, G | 1 |
| Chen, Y | 1 |
| Dai, L | 1 |
| Brookes, PS | 1 |
| Darley-Usmar, VM | 1 |
| Anderson, PG | 1 |
| Gealekman, O | 1 |
| Abassi, Z | 1 |
| Rubinstein, I | 1 |
| Winaver, J | 1 |
| Binah, O | 1 |
3 other studies available for n-(3-(aminomethyl)benzyl)acetamidine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure.
Topics: Amidines; Animals; Aortic Diseases; Atrial Natriuretic Factor; Benzylamines; Cardiomegaly; Chronic D | 2007 |
Bioenergetics in cardiac hypertrophy: mitochondrial respiration as a pathological target of NO*.
Topics: Amidines; Animals; Benzylamines; Cardiomegaly; Cell Respiration; Energy Metabolism; Enzyme Inhibitor | 2001 |
Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure.
Topics: Adrenergic beta-Agonists; Amidines; Animals; Arteriovenous Fistula; Benzylamines; Calcium; Cardiac V | 2002 |